EN
EN
FR
ES
PT
AR
RU
DE
IT
NL
TH
KO
VI
ID
Home
Kexing Biopharm
About Us
Kexing Brand
Brand Connotation
Corporate Culture
Honors
History
Global Business
Global Commercial Cooperation Strategy
Commercialization platform
Commercialization capability
Commercial Cooperation Graph
R&D and Innovation
Global R&D Center
R&D field
Animal Vaccine
SANCTINUS
Our Medicines
Infliximab for Injection
Bevacizumab Injection
Adalimumab Solution for Injection
Paclitaxel for Injection(Albumin-Bound)
Human Erythropoietin Injection
Human Granulocyte Colony-stimulating Factor Injection
Combined Clostridium Butyricum and Bifidobacterium Capsule, Live
Human Interferon α1b for Injection
Kehuang Capsule
Entecavir Tablets
α-ketoglutarate(AKG)
5-aminnolevulinic acid (5-ALA)
Recombinant Collagen Repair Mask
Recombinant Collagen Anti-Wrinkle Single Use Essence
Aflibercept Intravitreous Injection
Denosumab
Enzalutamide Soft Capsules
Sitagliptin Phosphate Tablets
Liraglutide Injection
Sevelamer Carbonate Tablets
Olaparib Tablets
Sorafenib Tablets
Eribulin Mesylate Injection
Neratinib Maleate Tablets
Lenalidomide Capsules
Trastuzumab Injection
Palbociclib Capsules
Semaglutide Injection
Quality Control
Quality system
Compliant production
Pharmacovigilance
ESG
Global health
Support Community
Environmental protection
News
News and Innovation
Video Center
Contact
Contact Us
Join Us
NEWS AND INFORMATION
Home
/
Key Products: S...
Key Products: Summary Prescribing Information
Article source：
Sep 30,2026
View： 1378
LABEL:
< No Prev
Kexing Biopharm Product Introduction 2026 >
BACK TO LIST
Related News
Jun 09,2026
Kexing Biopharm Product Introduction 2026
READ MORE >>
Oct 06,2023
Kexing Biopharm Holds China-MENA & South Asia Pharmaceutical Cooperation High-end Forum, Aiming at Foreign Emerging Markets
READ MORE >>
Aug 26,2026
Southeast Asian Market Progress! Kexing Biopharm’s licensed-in product Infliximab Biosimilar Reminton Approved for Marketing in Thailand
READ MORE >>
Mar 10,2026
Kexing Biopharm's Albumin-Bound Paclitaxel Product Approved in Multiple Regions
READ MORE >>
Apr 09,2026
Kexing Biopharm 's Overseas Commercial Product Albumin-Bound Paclitaxel with Marketing Approval in the Dominican Republic
READ MORE >>
Jun 09,2026
Kexing Biopharm Product Introduction 2026
READ MORE >>
Home
Kexing Biopharm
About Us
Kexing Brand
Brand Connotation
Corporate Culture
Honors
History
Global Business
Global Commercial Cooperation Strategy
Commercialization platform
Commercialization capability
Commercial Cooperation Graph
R&D and Innovation
Global R&D Center
R&D field
Animal Vaccine
SANCTINUS
Our Medicines
Infliximab for Injection
Bevacizumab Injection
Adalimumab Solution for Injection
Paclitaxel for Injection(Albumin-Bound)
Human Erythropoietin Injection
Human Granulocyte Colony-stimulating Factor Injection
Combined Clostridium Butyricum and Bifidobacterium Capsule, Live
Human Interferon α1b for Injection
Kehuang Capsule
Entecavir Tablets
α-ketoglutarate(AKG)
5-aminnolevulinic acid (5-ALA)
Recombinant Collagen Repair Mask
Recombinant Collagen Anti-Wrinkle Single Use Essence
Aflibercept Intravitreous Injection
Denosumab
Enzalutamide Soft Capsules
Sitagliptin Phosphate Tablets
Liraglutide Injection
Sevelamer Carbonate Tablets
Olaparib Tablets
Sorafenib Tablets
Eribulin Mesylate Injection
Neratinib Maleate Tablets
Lenalidomide Capsules
Trastuzumab Injection
Palbociclib Capsules
Semaglutide Injection
Quality Control
Quality system
Compliant production
Pharmacovigilance
ESG
Global health
Support Community
Environmental protection
News
News and Innovation
Video Center
Contact
Contact Us
Join Us
Article source：
Sep 30,2026
View：
1378 
BACK TO LIST
Jun 09,2026
